DSGN - Design Therapeutics, Inc.
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs.
As of May 29, 2026: spot at $10.43, ATM IV 436.9%, max pain $10.00, net GEX $174.7K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $693.3M
- Beta
- 1.74
- 52-Week Range
- 3.33-17.25
- CEO
- Pratik Shah
- Employees
- 56
- IPO Date
- Mar 29, 2021
- Exchange
- NASDAQ
What DSGN Looks Like to Options Traders Today
IV rank of 96.8% signals elevated pricing relative to the 1-year history, conditions that typically favor premium-selling structures (credit spreads, iron condors, covered calls); positive net gamma exposure ($174.7K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (-1.103) prices puts richer than calls, the typical equity downside-protection skew.
What This Page Covers
The DSGN overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked DSGN overview questions
- What is DSGN?
- DSGN is the ticker symbol for Design Therapeutics, Inc., a listed security. Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. Listed on NASDAQ. DSGN is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the DSGN options snapshot look like today?
- As of May 29, 2026, the DSGN options snapshot shows spot at $10.43, ATM IV 436.9%, IV rank 96.8%, max pain $10.00, net GEX $174.7K, expected move 125.26%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are DSGN's key statistics?
- Design Therapeutics, Inc. (DSGN) carries a market capitalization of $693.3M, beta of 1.74 relative to the broader market, 52-week range of 3.33-17.25. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does DSGN belong to?
- Design Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare DSGN's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the DSGN data on this page?
- The options snapshot above is dated May 29, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).